Clinical Trials at Wolfe Eye Clinic
Wolfe Eye Clinic has a long history of participation in vision research in areas such as retinal disease, cataract and laser vision correction surgery.
The tradition continues today with our involvement in national studies across multiple disciplines including diabetic eye disease, macular degeneration, glaucoma and pediatric ophthalmology. We believe our research work in these areas will aid better treatment and outcomes for these eye diseases leading to an improved quality of life for many.
Recruiting Clinical Trials
Wet Age-Related Macular Degeneration (AMD):
A Randomized Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT05407636
Dry Age-Related Macular Degeneration (AMD):
Intermediate Dry AMD
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration (HONU)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT05300724
Geographic Atrophy (GA)
A Study to Evaluate the Safety and Efficacy of Two Doses of GT005 (EXPLORE)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04437368
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (ALEXION)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT05019521
Diabetic Retinopathy:
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening (Protocol AF)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04661358
Active Clinical Trial Studies
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (AVONELLE-X)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04777201
A Prospective, Enrolled, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO) (BEACON)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04592419
A Prospective, Enrolled, Double-masked, Active Comparator controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME) (GLEAM)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04611152
An Open Label First in Human Phase 1 & 2 Multicentre Study to Evaluate the Safety, Dose Response and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects with Macular Atrophy Due to Age-Related Macular Degeneration (FOCUS)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03846193
A Phase II, Open-Lab, Outcomes-Assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (HORIZON)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04566445
Enrolled, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patient with Neovascular Age-Related Macular Degeneration (PULSAR)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04423718
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration (PORTAL)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03683251
Completed Clinical Trial Studies
A 64-week, Two-Arm, Enrolled, Double-Masked, Multi-Center, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-Control Regimen in Patients with Neovascular Age-Related Macular Degeneration (TALON)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04005352
A Phase 3 Multicenter, Enrolled, Double-Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura™ (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (ISEE2008)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04435366
Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Wet Age-related Macular Degeneration (DAYLIGHT)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04964089
A Phase 2, Prospective, Enrolled, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-related Macular Degeneration (DAZZLE)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04049266
A Phase II, Multicenter, Enrolled, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03972709
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03622580
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02634333
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (ARCHWAY)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03677934
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04503551
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (PAGODA)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT04108156
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03710564
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (DME)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03917472
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD (ALTISSIMO)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03953079
Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03397264
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03038880
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System (RPDS) for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) (LADDER)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02510794
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02713204
A Study of Faricimab (RO6867461) in Participants With Center-involving Diabetic Macular Edema (BOULEVARD)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02699450
A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02686658
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02745119
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02247479
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02247531
A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02424019
The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) (TIME-2b)
Learn more here: https://clinicaltrials.gov/ct2/show/NCT03197870
A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration
Learn more here: https://clinicaltrials.gov/ct2/show/NCT02307682
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab (FCFD4514S) in Patients With Geographic Atrophy Who Have Completed Genentech-Sponsored Lampalizumab Studies
Learn more here: https://clinicaltrials.gov/ct2/show/NCT01602120